ENOB CV 01
Alternative Names: ENOB-CV-01Latest Information Update: 21 Aug 2023
At a glance
- Originator G-Tech Bio
- Developer Renovaro Biosciences
- Class Antivirals; Gene therapies; Oligonucleotides; RNA
- Mechanism of Action Apoptosis stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 09 Aug 2023 Enochian BioSciences is now called Renovaro Biosciences
- 26 Jun 2021 Enochain Bioscience entered a licensing agreement with G Tech Bio, LLC and Seraph Research Institute for the treatment of COVID-2019 infections (Enochian Bioscience pipeline June 2021)
- 26 Jun 2021 Enochian BioSciences plans to submit Pre-Investigator New Drug meeting request for the treatment of COVID-2019 infections to the US FDA